Aromando Andrew 4

What Happened
Aromando Andrew, Chief Business Officer of Oncolytics Biotech Inc. (ONCY), purchased 29,600 shares on Feb 11, 2026. The reported total cost was $25,418, with a weighted average price of $0.86 per share (prices in the purchases ranged $0.85–$0.86). This was a purchase (transaction code P), which is a direct acquisition of common stock.

Key Details

• Transaction date: February 11, 2026. Form 4 filed on February 13, 2026 (appears timely under the two-business-day rule).
• Shares acquired: 29,600; reported weighted-average price: $0.86; total reported value: $25,418.
• Price range: individual trades were executed at prices between $0.85 and $0.86 (footnote F1). The reporting person can provide a breakdown of how many shares were bought at each price on request.
• Shares owned after the transaction: Not specified in the provided filing details.
• Transaction code: P (purchase / open-market or private purchase).

Context
Purchases by executives can be interpreted by some investors as a positive signal because they increase the insider’s stake, but filings do not state motivation—be factual and avoid assuming intent. This report documents a small-dollar open-market purchase rather than an option exercise, gift, or planned sale.